2.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.54
Aprire:
$2.661
Volume 24 ore:
110.26K
Relative Volume:
0.54
Capitalizzazione di mercato:
$79.60M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-2.0338
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
+10.53%
1M Prestazione:
+39.29%
6M Prestazione:
-8.08%
1 anno Prestazione:
-30.71%
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta VTGN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VTGN
Vistagen Therapeutics Inc
|
2.73 | 74.06M | 875.70K | -39.57M | -33.65M | -1.3423 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
2022-07-22 | Downgrade | Jefferies | Buy → Hold |
2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
2021-05-20 | Iniziato | Robert W. Baird | Outperform |
2021-02-18 | Iniziato | Jefferies | Buy |
2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2018-06-27 | Iniziato | Maxim Group | Buy |
2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional
Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com
What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
Vistagen Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What makes Vistagen Therapeutics Inc. stock price move sharply2x Return Forecast - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat
Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru
How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan
Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus
Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com
William Blair Issues Negative Forecast for VTGN Earnings - Defense World
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey
William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat
Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise
Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):